Genesis Drug Discovery & Development Acquires Comparative Biosciences (CBI)

August 5, 2020

Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group (GBG), has acquired Comparative Biosciences, Inc. (CBI), a Sunnyvale-based preclinical CRO. The acquisition adds GLP toxicology and safety pharmacology capabilities to GD3/GBG's integrated preclinical services, enabling end-to-end IND-enabling studies and expanding GD3's service offering.

Buyers
Genesis Drug Discovery & Development (GD3), Genesis Biotechnology Group (GBG)
Targets
Comparative Biosciences, Inc. (CBI)
Industry
Biotechnology
Location
California, United States
Transaction Type
Buyout

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →